As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
COVID-19 and impact on peer review
Article publication charge discount
All authors submitting to Hereditary Cancer in Clinical Practice are eligible for partial coverage of the journal’s article-processing charge (APC).
This discount must be requested before the View Publication Charges page by emailing the Journal Development Editor at email@example.com for a code. Authors will not have to pay the full APC themselves if the article is accepted.
Aims and scope
Hereditary Cancer in Clinical Practice is an open access journal that publishes articles of interest for the cancer genetics community and serves as a discussion forum for the development appropriate healthcare strategies.
Cancer genetics encompasses a wide variety of disciplines and knowledge in the field is rapidly growing, especially as the amount of information linking genetic differences to inherited cancer predispositions continues expanding. With the increased knowledge of genetic variability and how this relates to cancer risk there is a growing demand not only to disseminate this information into clinical practice but also to enable competent debate concerning how such information is managed and what it implies for patient care. Read more.
Meet the Editors-in-Chief
Jan Lubinski is a Professor of Medicine and Head of the International Hereditary Cancer Center (organized in 1992) of Pomeranian Medical University in Szczecin, Poland. The center conducted the first world-wide population screening for cancer family syndromes in a 1.7 million region of West-Pomerania, Poland in 2000-2001. It has a network of outpatient clinics covering almost the entire country as well as a cancer bio-bank with biological samples and clinical data from 250,000 cancer cases and appropriate controls, which includes registries of thousands of mutation carriers.
Rodney J. Scott graduated from the University of Western Australia, Australia with a PhD in cellular biology and subsequently worked in the Department of Pathology and Laboratory Medicine at the University of Texas in Houston and then at the Centre for Teaching and Learning at the University of Basel, Switzerland. Since 1999 Prof. Scott has been a visiting Professor at the International Hereditary Cancer Center in Szczecin, Poland and more recently has been appointed as a adjunct Professor at the Universiti Kebangsaan Malaysia.
Annual Journal Metrics
86 days to first decision for reviewed manuscripts only
70 days to first decision for all manuscripts
131 days from submission to acceptance
15 days from acceptance to publication
91 Altmetric Mentions